Comparative Pharmacology
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus REVONTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOBENZAPRINE HYDROCHLORIDE versus REVONTO.
CYCLOBENZAPRINE HYDROCHLORIDE vs REVONTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
Remimazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, enhancing the effects of GABA to produce sedation and anxiolysis.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
4 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Terminal elimination half-life is approximately 18–20 hours in healthy adults, allowing once-daily dosing.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
Renal excretion of unchanged drug accounts for <1% of the dose; fecal excretion via biliary elimination is the primary route (≈90%), with the remainder as metabolites.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant